Background
cardiovascular disease
EVENTS, SECONDARY, CARDIOVASCULAR DISEASE
A complete list of the REVEAL Collaborative Group members can be found in the Supplemental Material.Despite optimized risk factor control, people with prior cardiovascular disease remain at high cardiovascular disease risk. We assess the immediate‐ and longer‐term impacts of new vascular and nonvascular events on quality of life (QoL) and hospital costs among participants in the REVEAL (Randomized Evaluation of the Effects of Anacetrapib Through Lipid Modification) trial in secondary prevention.